Studies

Wang Y, Van Nieuwenhuysen E, Revheim ME, Deroose CM, Eriksson AGZ, Eyjolfsdottir B, Van Gorp T, Baert T, Aksnes AK, Myren K, Vergote I, Bruland ØS (2025)
First experience with intraperitoneal ²²⁴Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer
Gynecol Oncol, 204, 158-164 (in press)
DOI 10.1016/j.ygyno.2025.11.018, PubMed 41349345

Harter P, Marmé F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, Ray-Coquard I, Garcia-Duran C, Jonuskiene G, Heitz F, Béllier C, Pérez-Fidalgo JA, El-Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges A et al. (2025)
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
J Clin Oncol, JCO2501210 (in press)
DOI 10.1200/JCO-25-01210, PubMed 41337696

Corbaux P, You B, Kagimura T, Glasspool RM, McNeish I, Cook A, Mirza MR, Lindemann K, Tinker AV, Welch S, Ray-Coquard IL, Subtil F, Colomban O, Péron J, Karamouza E, Kelly C, Lewsley LA, Paoletti X, Yanaihara N (2025)
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis
Int J Gynecol Cancer, 36 (1), 102719 (in press)
DOI 10.1016/j.ijgc.2025.102719, PubMed 41259844